Astellas Pharma Inc Unsponsored ADR (ALPMY) – FDA
-
Pfizer (PFE) Announces EMA Validates Type II Variation Application for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
-
Astellas, Seagen (SGEN) Receive Positive CHMP Opinion for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ALPMY Stock Lookup